SCHEMBL2730940

SCHEMBL2730940

CC(=O)Nc1ccc(NC(=O)Nc2ccc(B3OC(C)(C)C(C)(C)O3)cc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 9/20 0.53
CA2 P00918 9/20 0.53
CA9 Q16790 9/20 0.53
KMT2A Q03164 3/20 0.53
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53
TAAR1 Q96RJ0 1/20 0.53
CA12 O43570 2/20 0.51
CA3 P07451 2/20 0.51
CA4 P22748 2/20 0.51
CA7 P43166 2/20 0.51
CA14 Q9ULX7 2/20 0.51
CA6 P23280 1/20 0.51
CA5A P35218 1/20 0.51
CA5B Q9Y2D0 1/20 0.51
PDGFRB P09619 2/20 0.49
KDR P35968 2/20 0.49
MEN1 O00255 2/20 0.49
HTT P42858 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1284377 0.95 CA1 (0.57) CA1CA2CA9KMT2ARAB9A
SCHEMBL14942938 0.88 CA1 (0.57) CA1CA2CA9KMT2ANPC1
SCHEMBL423204 0.88 PDGFRB (0.61) CA1CA2CA9KMT2ANPC1
SCHEMBL422455 0.86 LPL (0.61) CA1CA2CA9KMT2ANPC1
SCHEMBL441861 0.86 CA1 (0.54) CA1CA2CA9KMT2ACA12
SCHEMBL443510 0.85 MDM2 (0.56) CA1CA2CA9KMT2ARAB9A
SCHEMBL29919236 0.84 CA1 (0.53) CA1CA2CA9CA12CA3
SCHEMBL440627 0.84 CNR1 (0.57) CA1CA2CA9KMT2ANPC1
SCHEMBL23977678 0.84 NOX1 (0.52) CA1CA2CA9KMT2ANPC1
SCHEMBL442711 0.84 CA1 (0.50) CA1CA2CA9CA12CA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9115092-B2 Substituted quinazoline and pyrido-pyrimidine derivatives ASANA BIOSCIENCES, LLC (US) 2015-08-25 US disclosed
US-20150011547-A1 SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES ASANA BIOSCIENCES, LLC (US) 2015-01-08 US disclosed
US-20140073782-A1 Substituted Quinazoline and Pyrido-Pyrimidine Derivatives ENDO PHARMACEUTICALS INC. (US) 2014-03-13 US disclosed
US-20130190492-A1 SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES ENDO PHARMACEUTICALS INC. (US) 2013-07-25 US disclosed
US-8440662-B2 Substituted quinazoline and pyrido-pyrimidine derivatives ENDO PHARMACEUTICALS, INC. (US) 2013-05-14 US disclosed
US-20120129851-A1 Substituted Quinazoline and Pyrido-Pyrimidine Derivatives ENDO PHARMACEUTICALS INC. (US) 2012-05-24 US disclosed
WO-2012058671-A1 SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES ENDO PHARMACEUTICALS INC. (US) 2012-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140073782-A1 Substituted Quinazoline and Pyrido-Pyrimidine Derivatives MTOR, PIK3CA, PDPK1 CA1 4821/4885CA2 3805/4885CA9 3527/4885
US-20130190492-A1 SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES MTOR, PIK3CA, PDPK1 CA1 4821/4885CA2 3805/4885CA9 3527/4885
US-20150011547-A1 SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES MTOR, PIK3CA, PDPK1 CA1 4821/4885CA2 3805/4885CA9 3527/4885
US-20120129851-A1 Substituted Quinazoline and Pyrido-Pyrimidine Derivatives MTOR, PIK3CA, PDPK1 CA1 4821/4885CA2 3805/4885CA9 3527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.